-
Mavoglurant (developmental code name AFQ-056) is an
experimental drug
candidate for the
treatment of
fragile X
syndrome and
other conditions. It exerts...
-
alternate NYSE
symbol Afloqualone AFQ1,
metabolite of
aflatoxin AFQ-056 (
Mavoglurant),
experimental drug
candidate AF (disambiguation) FAQ This disambiguation...
-
Ibotenic acid
Quisqualic acid VU-1545 Antagonists: CTEP
DMeOB LY-344,545
Mavoglurant MCPG NPS-2390
Remeglurant SIB-1757 SIB-1893;
Negative allosteric modulators:...
- and may show
promise in the
treatment of FXS. Two new drugs, AFQ-056 (
mavoglurant) and dipraglurant, as well as the
repurposed drug
fenobam are currently...
-
Ibotenic acid
Quisqualic acid VU-1545 Antagonists: CTEP
DMeOB LY-344,545
Mavoglurant MCPG NPS-2390
Remeglurant SIB-1757 SIB-1893;
Negative allosteric modulators:...
-
Ibotenic acid
Quisqualic acid VU-1545 Antagonists: CTEP
DMeOB LY-344,545
Mavoglurant MCPG NPS-2390
Remeglurant SIB-1757 SIB-1893;
Negative allosteric modulators:...
-
Ibotenic acid
Quisqualic acid VU-1545 Antagonists: CTEP
DMeOB LY-344,545
Mavoglurant MCPG NPS-2390
Remeglurant SIB-1757 SIB-1893;
Negative allosteric modulators:...
-
Ibotenic acid
Quisqualic acid VU-1545 Antagonists: CTEP
DMeOB LY-344,545
Mavoglurant MCPG NPS-2390
Remeglurant SIB-1757 SIB-1893;
Negative allosteric modulators:...
-
Ibotenic acid
Quisqualic acid VU-1545 Antagonists: CTEP
DMeOB LY-344,545
Mavoglurant MCPG NPS-2390
Remeglurant SIB-1757 SIB-1893;
Negative allosteric modulators:...
-
Ibotenic acid
Quisqualic acid VU-1545 Antagonists: CTEP
DMeOB LY-344,545
Mavoglurant MCPG NPS-2390
Remeglurant SIB-1757 SIB-1893;
Negative allosteric modulators:...
